Biology Reference
In-Depth Information
Lahu G, Huennemeyer A, Herzog R, McCracken N, Hermann R, Elmlinger M, Zech K (2009)
Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast
N-oxide. Int J Clin Pharmacol Ther 47:236-245
Lahu G, H
unnemeyer A, Diletti E et al (2010) Population pharmacokinetic modelling of roflumilast
and roflumilast N-oxide by total phosphodiesterase 4 inhibitory activity and development of
a population pharmacodynamic-adverse event model. Clin Pharmacokinet 49:589-606
Lahu G, Nassr N, Herzog R, Elmlinger M, Ruth P, Hinder M, Huennemeyer A (2011) Effect of
steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.
J Clin Pharm 15:586-593
Lim S, Tomita K, Caramori G, Jatakanon A, Oliver B, Keller A, Adcock I, Chung KF, Barnes PJ
(2001) Low-dose theophylline reduces eosinophilic inflammation but not exhaled nictric oxide
in mild asthma. Am J Respir Crit Care Med 164:273-276
Laux G, Becker T, Kuhne G, Lesch KP, Riederer P, Beckmann H (1988) Clinical and biochemical
effects of the selective phosphodiesterase inhibitor rolipram in depressed inpatients controlled
by determination of plasma levels. Pharmacopsychiatry 21:378-379
Maeda S, Ishida R, Komuro M, Ohmuro S, Hashimoto H, Hotta M, Uchida H (1989) Studies of
KC-404 (3-Isobutyryl-2-isopropylpyrazolo-[1,5-apyridine]) pharmacokinetics
€
in humans
(Report 2). Clin Rep (Kiso to Rinsho) 23:183-189 (in Japanese)
Mallikaarjun S, Shoaf S, Zhang P, Mitsui K, Molfino NA (2006) Pharmacokinetics (PK) and
pharmacodynamics (PD) of tetomilast in stable COPD subjects. Eur Respir J 661s, P3838
(abstract)
Martina SD, Ismail MS, Vesta KS (2006) Cilomilast: orally active selective phosphodiesterase-4
inhibitor for treatment of chronic obstructive pulmonary disease. Ann Pharmacother 40:1822-1828
McCann FE, Palfreeman AC, Andrews M, Perocheau DP, Inglis JJ, Schafer P, Feldman M,
Willaims RO, Brennan FM (2010) Apremilast, a novel PDE4 inhibitor, inhibits spontaneous
production of tumor necrosis factor-alpha from human rheumatoid synovial cells and amelio-
rates experimental arthritis. Arthritis Res Ther 12:R107
McCracken N, Lahu G, Bethke TD (2011) Lack of pharmacokinetic and pharmacodynamic
interactions of roflumilast with (R, S)-Warfarin in healthy adult subjects J Clin Pharmacol
(in press)
Murdoch R, Cowley H, Webber D, Tayloer H (1998) The addition of SB207499 (Ariflo), a novel &
selective PDE4 inhibitor to oral prednisolone is safe & well tolerated (from study). Eur Respir J
12(Suppl 28):362S
Murdoch RD, Cowley H, Kelly J, Higgins R, Webber D (2002) Cilomilast (Ariflo) does not
potentiate the cardiovascular effects of inhaled salbutamol. Pulm Pharmacol Ther 15:521-527
Murdoch RD, Zussman B, Schofield JP, Webber DM (2004) Lack of pharmacokinetic interactions
between cilomilast and theophylline or smoking in healthy volunteers. J Clin Pharmacol 44:
1046-1053
Nassr N, Lahu G, von Richter O, Reutter F, Knoerzer D, Zech K, Erb KA, Schug B, Blume H,
Hermann R (2007a) Lack of a pharmacokinetic interaction between steady-state roflumilast
and single-dose midazolam in healthy subjects. Br J Clin Pharmacol 63:365-370
Nassr N, Lahu G, Hunnemeyer A, von Richter O, Knoerzer D, Reutter F, Zech K, Hermann R
(2007b) Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the
pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast. J Clin Pharmacol
47:660-666
Nassr N, Huennemeyer A, Herzog R, von Richter O, Hermann R, Koch M, Duffy K, Zech K,
Lahu G (2009) Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast
N-oxide in healthy subjects. Br J Clin Pharmacol 68:580-587
Nazarian R, Weinberg JM (2009) AN-2728, a PDE4 inhibitor for the potential topical treatment of
psoriasis and atopic dermatitis. Curr Opin Investig Drugs 10:1236-1242
Ohta K, Fukuchi Y, Grouse L, Mizutani R, Rabe KF, Rennard SI, Zhong NS (2004) A prospective
clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respir Med 98:
1016-1024
